

# CONTROL SO COMPLETE, IT'S LIKE YOU'RE ALWAYS THERE



Defend their wounds between weekly debridements with PuraPly® AM—the unique combination of native, cross-linked ECM + broad-spectrum PHMB that provides a sustained antimicrobial barrier to keep you in command of the healing environment all week long.<sup>1-3</sup>

Organogenesis

PuraPly® AM

Antimicrobial Wound Matrix

# INDEPENDENTLY UNIQUE, COLLECTIVELY IN CONTROL

## NATIVE, CROSS-LINKED ECM

Helps support healing<sup>4,5</sup>

Unlike fragmented, reconstituted collagen:

- Native ECM inhibits a wider range of MMPs, helping to address the proteolytic environment that stalls wounds<sup>6</sup>
- The cross-linked, dual layers of PuraPly<sup>®</sup> AM resist ECM degradation in the wound, supporting persistence between debridements<sup>2</sup>
- The dual layers of PuraPly AM maximize surface area for PHMB saturation<sup>3,7,8</sup>

## BROAD-SPECTRUM PHMB

Proactively disrupts bioburden<sup>3,8,9</sup>

Unlike silver dressings, PHMB:

- Won't damage key cells (eg, fibroblasts) involved in wound healing<sup>10</sup>
- Features high tissue compatibility and low cytotoxicity<sup>9,11,12</sup>
- Has no known instances of bacteria acquiring resistance<sup>8,9,11,13</sup>

ECM=extracellular matrix; MMP=matrix metalloproteinases; PHMB=polyhexamethylene biguanide

## THE POWER OF PLUS

Only PuraPly AM features the unique combination of native, cross-linked ECM + broad-spectrum PHMB to:

Provide a sustained antimicrobial barrier effect<sup>1,2</sup>

Act as a bridge between weekly debridements<sup>2</sup>



Help prevent biofilm re-formation<sup>2</sup>

Keep you in control of the healing environment

## PURAPLY AM

NATIVE,  
CROSS-LINKED  
ECM



BROAD-SPECTRUM  
PHMB



Learn more about the new standard of care at [PuraPlyAM.com](http://PuraPlyAM.com)

Please refer to the PuraPly AM directions for use for complete prescribing information at [PuraPlyAM.com](http://PuraPlyAM.com)

Manufactured and distributed by: Organogenesis Inc. Canton, MA 02021

**References:** **1.** Data on file. PDR-0001. Organogenesis Inc. **2.** Data on file. PDR-0002. Organogenesis Inc. **3.** PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc.; 2015. **4.** Oropallo AR. *Plast Reconstr Surg Glob Open.* 2019;7:e2047. **5.** Lintzeris D, et al. *Wounds.* 2018;30(3):72-78. **6.** Negron L, et al. *Int Wound J.* 2014;11(4):392-397. **7.** Carpenter S, et al. *Wounds.* 2016;28(6 suppl):S1-S20. **8.** Brantley J, et al. *Wounds Int.* 2016;7(3):1-5. **9.** Gilbert P, et al. *J Appl Microbiol.* 2005;99(4):703-715. **10.** Zou SB, et al. *Int Wound J.* 2013;10(3):306-312. **11.** Hübner NO, et al. *Skin Pharmacol Physiol.* 2010;23(1 suppl):17-27. **12.** Sood A, et al. *Adv Wound Care.* 2014;3(8):511-529. **13.** Sim W, et al. *Antibiotics.* 2018;7(4):93.